TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16586550
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole
Study: 16586550
Drug: Protective agent
Normalized name: PROTECTIVE AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective agent of gastric mucosa (tepretone)
Study: 8808130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluvoxamine
Study: 8808130
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg dothiepin
Study: 30275528
Drug: S-HAM (dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-HAM (dose-dense induction)
Study: 27586232
Drug: Intravenous Magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Magnesium (Mg)
Study: 22610193
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (80-110 mg/dL)
Study: 22610193
Drug: Loose glycemic
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose glycemic control (120-150 mg/dL)
Study: 8653874
Drug: L-carnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (500 mg IV as a single bolus)
Study: 1558796
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative chemotherapy including mitomycin C (MMC), OK‐432, UFT, PSK, and 5‐fluorouracil (5‐FU) bolus injections for 5 days starting on postoperative day 2
Study: 1558796
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving therapy with MMC, OK‐432, UFT, PSK without 5‐FU
Study: 4026911
Drug: Azlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Study: 4026911
Drug: Mezlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Study: 4026911
Drug: Both azlocillin
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both azlocillin and mezlocillin (4 g, intravenous infusion)
Study: 31859723
Drug: Bacterial cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial cellulose biopolymer film and gel dressing
Study: 12551869
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol intake (5 categories: no alcohol or <1 drink monthly, 1 to 3 drinks monthly, 1 to 4 drinks weekly, 5 to 7 drinks weekly, > or =2 drinks daily)
Study: 8703660
Drug: Azapropazone 300
Normalized name: Azapropazone 300 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 300 mg
Study: 8703660
Drug: Azapropazone 600
Normalized name: Azapropazone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 600 mg
Study: 6424697
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium cromoglycate (SCG)
Study: 6786129
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium cromoglycate (SCG)
Study: 25885285
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (monotherapy)
Study: 25885285
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (combination therapy)
Study: 17497439
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus 1 ng/kg/min iloprost
Study: 9755350
Drug: Self-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management program for inhaler medication compliance (6 weeks)
Study: 7663491
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (0.2 mg salbutamol plus 0.2 mg budesonide t.i.d.)
Study: 7663491
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (0.2 mg salbutamol plus placebo t.i.d.)
Study: 7663491
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group follow-up (28-36 months)
Study: 7663491
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (continued treatment)
Study: 2562087
Drug: pH adjusted
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH adjusted 2% mepivacaine solution (pHAS)
Study: 2562087
Drug: Standard 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2% mepivacaine solution
Study: 368743
Drug: Progestogens (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogens (single oral doses)
Study: 31022403
Drug: Lanreotide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (120 mg subcutaneously every 4 weeks)
Study: 31022403
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (blood pressure control, sodium-restricted diet, antihypertensive agents)
Study: 18413439
Drug: Local cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cold therapy between -20 degrees C and -30 degrees C
Study: 18413439
Drug: Local cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cold therapy with glucocorticoids (GC)
Study: 7912948
Drug: Neostigmine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 1.5 mg and atropine 0.5 mg
Study: 12781313
Drug: Consultation‐Liaison Psychiatry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultation‐Liaison Psychiatry (C‐L Psychiatry) intervention; early screening with systematic multidisciplinary management for emotional disorders.
Study: 10940543
Drug: Pergolide 0.05
Normalized name: pergolide 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide 0.05 mg bid
Study: 10940543
Drug: Pergolide 0.25
Normalized name: pergolide 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide 0.25 mg bid
Study: 10940543
Drug: Pergolide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (both doses)
Study: 3291787
Drug: Combined measles,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined measles, mumps, and rubella vaccine
Study: 3291787
Drug: Single component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single component measles vaccine
Study: 31313720
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP (SuperNO2VA) at 10 cmH2O, oxygen flow rate of 15 l/min
Study: 31313720
Drug: Oxygen via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen via nasal cannula at 5 l/min
Study: 28198722
Drug: Stand-alone Physician
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone Physician Orders for Life-Sustaining Treatment (POLST) and living will (LW) documents
Study: 23556549
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV pre-treatment
Study: 9337947
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive therapy (BCT) plus 'treatment as usual'
Study: 9337947
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive therapy (BCT)
Study: 8210821
Drug: Transfer non-adherers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer non-adherers to alternative treatment group at randomization
Study: 8210821
Drug: Censor non-adherers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Censor non-adherers at time of treatment change
Study: 8210821
Drug: Transfer non-adherers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer non-adherers to alternative treatment group at time of treatment change
Study: 3320901
Drug: I.V. cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. cefuroxime (1.5 g)
Study: 27008297
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 2.5 µg dexmedetomidine
Study: 27008297
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 5 µg dexmedetomidine
Study: 27008297
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 10 µg dexmedetomidine
Study: 20107146
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg for infants, 20 mg for older children) for 4 months
Study: 14712886
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg uptitrated to 80 mg after four weeks, if needed)
Study: 8910097
Drug: 3‐carbon compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐carbon compounds pyruvate and dihydroxyacetone (PD)
Study: 28013097
Drug: Prequit Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prequit Nicotine Patch
Study: 28013098
Drug: Preparation Counseling
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation Counseling
Study: 28013098
Drug: 16 Weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 Weeks of Combination Nicotine Replacement Therapy (NRT)
Study: 28013098
Drug: 8 Weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 Weeks of Combination Nicotine Replacement Therapy (NRT)
Study: 27290960
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen trometamol
Study: 24398115
Drug: Relaxation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation and imagination therapies
Study: 20353109
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in active stage group
Study: 20353109
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in resting stage group
Study: 20353109
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in recovery stage group
Study: 2232833
Drug: Standard hypothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hypothermic cardioplegic solution
Study: 2232833
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution supplemented with deferoxamine 1000 mg/L
Study: 758132
Drug: Propylthiouracil (PTU)
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil (PTU) 300 mg daily
Study: 30190299
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle
Study: 30522967
Drug: Lomustine 110
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine 110 mg/m2 once every 6 weeks
Study: 25193976
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy for psychosis (CBTp)
Study: 25193976
Drug: Multi-modal Cognitive
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal Cognitive treatment (combination of CBTp and CAT)
Study: 21781528
Drug: Taxol and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol and cisplatin combined chemotherapy (TP)
Study: 20205024
Drug: Genetic/biological attributions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic/biological attributions of obesity
Study: 15266195
Drug: LISA-T prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: LISA-T prevention program (cognitive-behavioral therapy concepts, 10 meetings of 1.5 hours)
Study: 9150331
Drug: Home intravenous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intravenous (i.v.) antibiotic therapy
Study: 8429112
Drug: Zofenopril calcium
Normalized name: zofenopril calcium
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril calcium (7.5 mg, 15 mg, 30 mg)
Study: 3113280
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 10 mg four times daily
Study: 19626326
Drug: CT colonography
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT colonography with limited bowel preparation (180 ml diatrizoate meglumine, 80 ml barium, 30 mg bisacodyl)
Study: 19626326
Drug: Colonoscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy with full preparation (4 l of polyethylene glycol solution)
Study: 16579802
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (various doses)
Study: 16579802
Drug: Flax oil
Normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax oil (2.2 g of alpha-linolenic acid per day)
Study: 1577155
Drug: i.v. salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. salbutamol treatment (5 micrograms.kg‐1)
Study: 1577155
Drug: inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhaled salbutamol (0.15 mg.kg‐1 x 2)
Study: 6515508
Drug: Amoxycillin 1500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1500 mg/d for 2 weeks and 1000 mg/d for 12 weeks thereafter
Study: 6515508
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate 1500 mg/d for 2 weeks and 1000 mg/d for 12 weeks thereafter
Study: 27015283
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg plus naproxen 1,000 mg/day
Study: 27015283
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus naproxen 1,000 mg/day
Study: 22584564
Drug: Intensive educational
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive educational intervention (GI) with six weekly visits
Study: 22584564
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (GC)
Study: 17999650
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion (HCl, 0.1 mol L(‐1))
Study: 14589461
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment of neck pain
Study: 1660823
Drug: Erythromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (10 g in 40 doses over 10 days)
Study: 1660823
Drug: Amoxycillin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (15 g in 30 doses over 10 days)
Study: 7138752
Drug: Combined formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formulation of long-acting propranolol/bendrofluazide (Inderex)
Study: 7138752
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three preparations (LA propranolol, LA propranolol and bendrofluazide, combined formulation)
Study: 7138752
Drug: Bendrofluazide in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide in two preparations
Study: 30132786
Drug: (-)-OSU6162 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-OSU6162 15 mg twice daily for 4 weeks, then 30 mg twice daily for 4 weeks, then 45 mg twice daily for 4 weeks
Study: 27725493
Drug: Prasugrel 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 20 mg
Study: 20374400
Drug: Computer-generated dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated dosing group (CGD)
Study: 17666020
Drug: 100 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mug vitamin K once daily
Study: 8002535
Drug: Benzodiazepine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine (1.5 mg lorazepam)
Study: 2907669
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg almitrine bismethylate
Study: 28732324
Drug: FEC-Doc (taxane-anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-Doc (taxane-anthracycline based chemotherapy)
Study: 26745107
Drug: Conventional Cytology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Cytology (CC)
Study: 23427334
Drug: Polydextrose (PDX)
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX) at a dose of 20 g/d
Study: 23427334
Drug: Soluble corn
Normalized name: soluble corn fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble corn fiber (SCF) at a dose of 20 g/d
Study: 8838821
Drug: Rice-based oral
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based oral rehydration solution (50 g/l)
Study: 2248588
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment following removal of the foreign body
Study: 6998553
Drug: High-dose methotrexate-citrovorum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate-citrovorum factor rescue plus cyclophosphamide (MECY)
Study: 26644527
Drug: Symptom monitoring
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom monitoring via tablet computers
Study: 24324046
Drug: Amlodipine-based treatment
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based treatment (NT-proBNP below median)
Study: 9850427
Drug: New amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: New amitriptyline tablet formulation (amitriptylin 25 von ct)
Study: 9850427
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (28.3 mg amitriptyline hydrochloride)
Study: 2679853
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metoclopramide with dexamethasone and lorazepam
Study: 30311085
Drug: 0.1 mg/mL
Normalized name: deanol 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/mL TBO
Study: 30311085
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TBO and diode laser
Study: 26438556
Drug: Oral sucrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose, 0.5 mL of 24% sucrose administered orally via syringe, 2 minutes before heel lancing.
Study: 23750463
Drug: Interpersonally focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonally focused therapy-cognitive behavioral analysis system of psychotherapy (CBASP)
Study: 7915773
Drug: IVIgG 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIgG 0.8 g/kg once
Study: 7915773
Drug: IVIgG 1
Normalized name: IVIgGM
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIgG 1 g/kg on 2 consecutive days
Study: 7915773
Drug: Intravenous anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-D 25 micrograms/kg on 2 consecutive days
Study: 7915773
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 4 mg/kg per day with tapering and discontinuation by day 21
Study: 2583258
Drug: 5-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug combination MOCCA
Study: 31307503
Drug: Nifurtimox (NFX)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox (NFX) 480 mg/day for 120 days
Study: 31307503
Drug: Benznidazole (BZN)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BZN) 300 mg/day for 60 days followed by placebo for 60 days
Study: 31307503
Drug: Benznidazole (BZN)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BZN) 150 mg/day for 120 days
Study: 31307503
Drug: Nifurtimox (NFX)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox (NFX) 240 mg/day for 120 days
Study: 22905856
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg once daily
Study: 8515544
Drug: Methylprednisolone (MPS)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPS) 15 mg.kg‐1 i.v. 60 minutes after CPB
Study: 8515544
Drug: No Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Methylprednisolone (MPS) administration
Study: 2835788
Drug: Topical LTB4
Normalized name: LTB4
DrugBank: Leukotriene B4 (DB12961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical LTB4 (100-900 ng applied once a week for up to 7 weeks depending on lesion type)
Study: 28941259
Drug: Aripiprazole (1–15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (1–15 mg/day)
Study: 24239295
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic capsules for 7 days
Study: 22266741
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% bupivacaine
Study: 19517661
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% bupivacaine with 0.5 mg neostigmine
Study: 15925049
Drug: Cetrorelix (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (GnRH antagonist)
Study: 15925049
Drug: Busereline (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busereline (GnRH agonist)
Study: 24798870
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg JNJ-41443532